UBASH3A Antibody (Center) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P57075 |
---|---|
Clone Names | 90713226 |
Gene ID | 53347 |
---|---|
Other Names | Ubiquitin-associated and SH3 domain-containing protein A, Cbl-interacting protein 4, CLIP4, Suppressor of T-cell receptor signaling 2, STS-2, T-cell ubiquitin ligand 1, TULA-1, UBASH3A, STS2 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | UBASH3A |
---|---|
Synonyms | STS2 |
Function | Interferes with CBL-mediated down-regulation and degradation of receptor-type tyrosine kinases. Promotes accumulation of activated target receptors, such as T-cell receptors, EGFR and PDGFRB, on the cell surface. Exhibits negligible protein tyrosine phosphatase activity at neutral pH. May act as a dominant-negative regulator of UBASH3B- dependent dephosphorylation. May inhibit dynamin-dependent endocytic pathways by functionally sequestering dynamin via its SH3 domain. |
Cellular Location | Cytoplasm. Nucleus. |
Tissue Location | Highest expression of UBASH3A in tissues belonging to the immune system, including spleen, peripheral blood leukocytes, thymus and bone marrow. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
UBASH3A interferes with CBL-mediated down-regulation and degradation of receptor-type tyrosine kinases. Promotes accumulation of activated target receptors, such as T-cell receptors, EGFR and PDGFRB, on the cell surface.
References
Hinks, A., et al. Ann. Rheum. Dis. (2010) In press :Stahl, E.A., et al. Nat. Genet. 42(6):508-514(2010)Jin, Y., et al. N. Engl. J. Med. 362(18):1686-1697(2010)Barrett, J.C., et al. Nat. Genet. 41(6):703-707(2009)Smyth, D.J., et al. N. Engl. J. Med. 359(26):2767-2777(2008)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.